High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

10 clinical trials · Condition

Record	Firm	Date
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)	National Cancer Institute (NCI)	2021-05-20
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956)	Mayo Clinic	2020-06-15
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (NCT03984448)	National Cancer Institute (NCI)	2019-10-22
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038)	Mayo Clinic	2018-03-23
Personalized NK Cell Therapy in CBT (NCT02727803)	M.D. Anderson Cancer Center	2016-05-19
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT02199184)	M.D. Anderson Cancer Center	2015-01-14
NK Cells in Cord Blood Transplantation (NCT01619761)	M.D. Anderson Cancer Center	2013-05-03

Every clearance here is in the API, with alerts when new ones post.